Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/216669| Title: | Treatment of granuloma annulare with tofacitinib |
| Author: | Bosch Amate, Xavier Serra García, Laura Alamon Reig, Francesc Martí Martí, Ignasi Gil Lianes, Javier Giavedoni, Priscila Mascaró Galy, José Manuel |
| Keywords: | Malalties de la pell Inhibidors enzimàtics Resposta immunitària Medicaments Skin diseases Enzyme inhibitors Immune response Drugs |
| Issue Date: | 1-Aug-2022 |
| Publisher: | Wiley |
| Abstract: | Granuloma annulare (GA) is a granulomatous, idiopathic, inflammatory skin disorder characterized by the formation of papules and plaques with annular and acral distribution. GA is often limited and self-resolving, but in some cases, it can be generalized and refractory to treatments. New advances in the pathophysiology of GA have favoured Janus kinase (JAK) inhibitors as a promising therapeutic option.1,2 Here, we report three cases of resistant generalized GA successfully treated with tofacitinib. |
| Note: | Reproducció del document publicat a: https://doi.org/10.1111/ajd.13875 |
| It is part of: | Australasian Journal of Dermatology, 2022, vol. 63, num.3, p. 400-403 |
| URI: | https://hdl.handle.net/2445/216669 |
| Related resource: | https://doi.org/10.1111/ajd.13875 |
| ISSN: | 0004-8380 |
| Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 870083.pdf | 1.98 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
